This multicenter randomized clinical trial conducted in France determines whether the addition of low-dose rivaroxaban to dual antiplatelet therapy reduces the incidence of left ventricular thrombus at 1 month in patients with anterior ST-segment elevation myocardial infarction.
JAMA Cardiology published a clinical update in Cardiology on 01 Apr 2026.
The item focuses on Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction.
Review the original article for the full source wording and details.